

# Merck Pipeline

1Q2026 Reflecting Pipeline to **20-Feb-2026**



## Lead-in language

The chart below reflects the company's research pipeline as of **20-Feb-2026**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

- 1. Being developed in a collaboration.
- ▶ Moved forward since last pipeline update.

# Merck pipeline as of 20-Feb-2026

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Biliary Bladder Cervical Endometrial Esophageal Gastric HCC HNSCC Melanoma NSCLC Ovarian Pancreatic Prostate patritumab deruxtecan <b>MK-1022<sup>1</sup></b>	▶ Solid Tumors calderasib <b>MK-1084<sup>1</sup></b>	Alzheimer's Disease <b>MK-1167</b>	Alzheimer's Disease <b>MK-2214</b>	Cancer Biliary Bladder Breast Cervical Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreatic ifinatamab deruxtecan <b>MK-2400<sup>1</sup></b>	Cancer Biliary Bladder Esophageal Neoplasm Malignant Pancreatic sacituzumab tirumotecan <b>MK-2870<sup>1</sup></b>
Cancer Bladder <b>MK-3120</b>	Cancer Prostate <b>KEYTRUDA®</b> <b>MK-3475</b>	Cancer Heme (US) <b>KEYTRUDA QLEX™</b> <b>MK-3475A</b>	PH-COPD <b>MK-5475</b>	Cancer Breast Endometrial Ovarian opevesostat <b>MK-5684</b>	COPD ensifentrine (+) glycopyrrolate <b>MK-5884A</b>

- 1. Being developed in a collaboration.
- ▶ Moved forward since last pipeline update.

# Merck pipeline as of 20-Feb-2026

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Bladder Cervical Endometrial Gastric NSCLC RCC SCLC raludotatug deruxtecan <b>MK-5909<sup>1</sup></b>	MASH efinopegdutide <b>MK-6024</b>	Cancer SCLC gocatamig <b>MK-6070<sup>1</sup></b>	Cancer Breast <b>WELIREG™</b> <b>MK-6482</b>	Immunology Axial Spondyloarthritis Hidradenitis Suppurativa Rheumatoid Arthritis Systemic Sclerosis tulisokibart <b>MK-7240</b>	Atherosclerosis <b>MK-7262</b>
Pulmonary Hypertension due to Left Heart Disease <b>WINREVAIR™</b> <b>MK-7962</b>	HIV-1 Infection islatravir (+) ulonivirine <b>MK-8591B</b>	Eye Disorders <b>MK-8748</b>	Cancer Bladder RCC intismeran autogene <b>V940<sup>1</sup></b>		

# Merck pipeline as of 20-Feb-2026

1. Being developed in a collaboration.
2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
3. Available in the U.S. under Emergency Use Authorization.
4. Program is in a Phase 2/3 study.

▶ Moved forward since last pipeline update.

Phase 3	Phase 3	Phase 3	Phase 3	Phase 3	Phase 3
Hypercholesterolemia enlicotide decanoate <b>MK-0616</b>	Cancer Breast patritumab deruxtecan <b>MK-1022</b> <sup>1</sup>	Cancer Heme nemtabrutinib <b>MK-1026</b>	Cancer CRC NSCLC calderasib <b>MK-1084</b> <sup>1</sup>	Cancer RCC quavonlimab (+) pembrolizumab <b>MK-1308A</b>	Influenza <b>MK-1406</b>
Cancer Heme zilovertamab vedotin <b>MK-2140</b>	Cancer Esophageal Prostate SCLC ifinatumab deruxtecan <b>MK-2400</b> <sup>1</sup>	Cancer Breast Cervical Endometrial Gastric NSCLC Ovarian sacituzumab tirumotecan <b>MK-2870</b> <sup>1</sup>	Diabetic Macular Edema <b>MK-3000</b> <sup>4</sup>	Cancer SCLC <b>KEYTRUDA</b> <sup>®</sup> <b>MK-3475</b>	Cancer Myeloproliferative Disorders bomedemstat <b>MK-3543</b>
COVID-19 <b>LAGEVRIO</b> <sup>®</sup> <b>MK-4482</b> <sup>1, 3</sup> (US)	Cancer Prostate opevesostat <b>MK-5684</b>	Ovarian raludotatug deruxtecan <b>MK-5909</b> <sup>1</sup>	Immunology Crohn's Disease Ulcerative Colitis tulisokibart <b>MK-7240</b>	Cancer NSCLC SCLC <b>LYNPARZA</b> <sup>®</sup> <b>MK-7339</b> <sup>1</sup>	HIV-1 PrEP <b>MK-8527</b>
HIV-1 Infection doravirine (+) islatravir <b>MK-8591A</b> (EU)	HIV-1 Infection islatravir (+) lenacapavir <b>MK-8591D</b> <sup>1,2</sup>	Dengue Fever Virus Vaccine <b>V181</b>	Cancer Melanoma NSCLC intismeran autogene <b>V940</b> <sup>1</sup>		

# Merck pipeline as of 20-Feb-2026

1. Being developed in a collaboration.
2. Under review for combination use with KEYTRUDA® or KEYTRUDA QLEX™.

▶ Moved forward since last pipeline update.

New Molecular Entities Under Review	New Molecular Entities Under Review
Respiratory Syncytial Virus clesrovimab <b>MK-1654 ENFLONIA™</b> (EU, JPN)	HIV-1 Infection doravirine (+) islatravir <b>MK-8591A</b> (US, JPN)

Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review
▶ Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) <b>KEYTRUDA® MK-3475</b> (EU, JPN)	▶ First Line Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (KND19) <b>KEYTRUDA® MK-3475</b> (US)	▶ First Line Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (KND19) <b>KEYTRUDA QLEX™ MK-3475A</b> (US)
▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) <b>KEYTRUDA® MK-3475</b> (EU, JPN)	▶ Clear Cell Renal Cell Carcinoma Following Nephrectomy (LITESPARK-022) <b>WELIREG® MK-6482<sup>1,2</sup></b> (US)	▶ Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-011) <b>WELIREG® MK-6482<sup>1</sup></b> (US)
▶ Pulmonary Arterial Hypertension (HYPERION) <b>WINREVAIR™ MK-7962</b> (US)		

# Merck pipeline as of 20-Feb-2026

1. Approvals obtained within the last 3 months.
2. MK-3475A to be marketed under the trade name KEYTRUDA SC in the EU.

▶ Moved forward since last pipeline update.

New Molecular Entities Approvals <sup>1</sup>	New Molecular Entities Approvals <sup>1</sup>
▶ Previously Approved Tumors <b>KEYTRUDA QLEX™</b> <b>MK-3475A<sup>2</sup></b> (EU)	▶ Pulmonary Arterial Hypertension (STELLAR) <b>WINREVAIR™</b> <b>MK-7962</b> (CHN)

Certain Supplemental Approvals <sup>1</sup>	Certain Supplemental Approvals <sup>1</sup>	Certain Supplemental Approvals <sup>1</sup>
▶ Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) <b>KEYTRUDA®</b> <b>MK-3475</b> (US)	▶ Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) <b>KEYTRUDA QLEX™</b> <b>MK-3475A</b> (US)	▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) <b>KEYTRUDA®</b> <b>MK-3475</b> (US)
▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) <b>KEYTRUDA QLEX™</b> <b>MK-3475A</b> (US)	▶ Primary Advanced or Recurrent Endometrial Carcinoma (KN868) <b>KEYTRUDA®</b> <b>MK-3475</b> (CHN)	▶ Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KN689) <b>KEYTRUDA®</b> <b>MK-3475</b> (JPN)
▶ Adults with Pulmonary Arterial Hypertension (WHO Functional Class (FC) II to III, and IV) (ZENITH) <b>WINREVAIR™</b> <b>MK-7962</b> (EU)		

# Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ([www.sec.gov](http://www.sec.gov)).

# No duty to update

The information contained in the presentation set forth below was current as of **20-Feb-2026**. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after **20-Feb-2026**.

The chart reflects the Merck research pipeline as of **20-Feb-2026**.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.